Pacific Therapeutics (PCFTF) 0.0070 $PCFTF Liver

New Post Public Reply Private Reply Replies (0) Message Board

Jul 12, 2015 at 3:53 AM

Pacific Therapeutics (PCFTF) 0.0070 $PCFTF

Liver Cirrhosis Pipeline Review, H1 2015 - 12 Key Comapnies
M2 - Thu Jun 11, 9:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2ctvbp/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alfa Wassermann S.p.A - Conatus Pharmaceuticals Inc. - Digna Biotech, S.L. - Galectin Therapeutics, Inc. - Gilead Sciences, Inc. - GNI Group Ltd. - Pacific Therapeutics Ltd. - PharmaIN Corporation - Pharmicell Co., Ltd. - S-Evans Biosciences, Inc. - Stelic Institute & Co. - Stempeutics Research Private Limited For more information visit http://www.researchandmarkets.com/research/2c..._cirrhosis
GILD: 113.74 (+0.38), CNAT: 4.83 (-0.09), GALT: 2.67 (+0.12)

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015
M2 - Tue Jun 02, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cp3333/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Aeolus Pharmaceuticals, Inc. - AnaptysBio, Inc. - Auspex Pharmaceuticals, Inc. - Biogen Idec Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Five Prime Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - HanAll Biopharma Co., Ltd. - Histocell S.L. - iBio, Inc. - ImmuneWorks, LLC - Inventiva SAS - Kadmon Corporation, LLC - Kasiak Research Pvt. Ltd. - Kyorin Pharmaceutical Co., Ltd. - Lanthio Pharma B.V. - LTT Bio-Pharma Co., Ltd. - MedImmune, LLC - Moerae Matrix, Inc. - MSM Protein Technologies, Inc. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Progenra, Inc. For more information visit http://www.researchandmarkets.com/research/cp3333/idiopathic
BIIB: 388.23 (-11.06), ASPX: 100.96 (unch), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), GILD: 113.74 (+0.38), CGEN: 6.63 (+0.06), IBIO: 0.86 (+0.01), FGEN: 22.82 (+0.58), CELGZ: 2.15 (+0.14), FPRX: 26.01 (+0.37)

Pacific Therapeutics Ltd. Announces United States Issuance of Patent for Treating Fibrosis
TheNewswire.ca - Mon Jun 01, 7:37AM CDT
(via Thenewswire.ca)
PT: 0.66 (-0.03)

IIROC Trade Resumption - PT
CNW Group - Tue May 19, 1:50PM CDT
Trading resumes in:

Pacific Therapeutics Signs LOI to Sell Fibrosis and Erectile Dysfunction Therapeutics Technologies
ACCESSWIRE - Tue May 19, 1:31PM CDT
VANCOUVER, BC / ACCESSWIRE / May 19, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (1P3.F) (the "Company"

is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.

IIROC Trading Halt - PT
CNW Group - Tue May 19, 1:22PM CDT
The following issues have been halted by IIROC:

Pacific Therapeutics Announces Extension of Temporary Re-Pricing of Outstanding Warrants
ACCESSWIRE - Tue Apr 28, 3:20PM CDT
VANCOUVER, BC / ACCESSWIRE / April 28, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"

is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.

Pacific Therapeutics Ltd. Announces Change Of Auditor
ACCESSWIRE - Wed Apr 22, 7:17PM CDT
VANCOUVER, BC / ACCESSWIRE / April 22, 2015 / Pacific Therapeutics Ltd. (CNSX: PT) (Frankfurt: 1P3) (the "Company"

announces that, effective April 22, 2015 it has changed auditors. on April 16, 2015 the Company announced the resignation of James Stafford Inc. Chartered Accountants as its auditor.
PT: 0.66 (-0.03)

Pacific Therapeutics Ltd. Announces United States Allowance of Patent for Treating Fibrosis
ACCESSWIRE - Fri Apr 10, 7:41AM CDT
VANCOUVER, BC / ACCESSWIRE / April 10, 2015 / Pacific Therapeutics Ltd. (CNSX: PT) (OTC

CFTF) (1P3.F) (the "Company"

is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing approved drugs for large markets.
PT: 0.66 (-0.03)

Pacific Therapeutics Announces Temporary Re-Pricing of Outstanding Warrants
ACCESSWIRE - Wed Apr 01, 6:15PM CDT
VANCOUVER, BC / ACCESSWIRE / April 1, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (PINKSHEETS: PCFTF) (Frankfurt: 1P3) (the "Company"

is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.

Pacific Therapeutics Announces Closing of Non-Brokered Financing
ACCESSWIRE - Mon Mar 23, 7:40AM CDT
VANCOUVER, BC / ACCESSWIRE / March 23, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (1P3.F) (the "Company"

is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.

Pacific Therapeutics Announces Non-Brokered Financing
ACCESSWIRE - Mon Feb 16, 1:12PM CST
VANCOUVER, BC / ACCESSWIRE / February 16, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (1P3.F) (the "Company"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

A. O. Smith Reports Q3 2026: A Strategic Shift

A. O. Smith Navigates Change in Third Quarter 2026 It's been a gritty third quarter for A. O. Smith, as the company maneuvers through domestic challenges and crafts a strategic future with international tweaks. They've hammered out $941 million in sales but found themselves grappling with net earnings dipping to $126 million, or $0.93 per diluted share, a mere blip from...

Oracle's Bold Vision: Targeting $225B Revenue by 2030

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

Banco Macro S.A. Plans $160B Share Buyback Initiative

Tapping into Share Buybacks in a Tumultuous Market Out of nowhere, Banco Macro S.A. has decided to whip up a share buyback program, a lifeline for their current market value. Let me tell you, the market's more volatile than a caffeinated squirrel these days, hitting the financial scenery harder than a hammer on a glass table. So, Banco Macro's taken a deep breath and...

Abbe Lane's Estate Auction: Glamour Up for Grabs

Glamour from the Mid-Century Comes to the Auction Block In a world obsessed with the flavor of the month, a collection that truly turns heads by sailing in on a wave of genuine mid-century splendor isn't something you stumble upon every day. John Moran Auctioneers has the privilege to crack open the vault on the Estate of Abbe Lane, a name that once rolled off tongues...

Booming Door Market: $105.93B by 2031, Key Insights

Introduction to the Future of the Door Industry Here's what gets me grinning—despite the market doomsayers, there's one industry that's swinging open new opportunities every year: doors. Projected to hit a whopping $105.93 billion by 2031, this market isn't just about hinges and handles. It's a sign of booming construction, urban development, and rising consumer...

Famous Brands Slashes Fees to Boost Franchise Growth

Throwing a Sweet Deal for New Franchise Owners Talk about a move that’s got the industry buzzing—Famous Brands International, the folks behind Mrs. Fields and TCBY, just rolled out a tantalizing offer you don’t see every day. They’re slashing franchise fees and royalties by half for new franchisees who jump onboard before the ball drops on 2026. I’ll tell ya,...

Fourth PAW Patrol Movie Announced by Spin Master

Spin Master and Paramount Roll the Dice Again Ah, Spin Master, you sly devils! Just when we thought they'd caught the last of those daring pups, they're back with another PAW Patrol flick. Yep, a fourth movie is revving up its engines, and this one's coming out of the gates in 2029, thanks to the trio of Spin Master Entertainment, Paramount Animation, and Nickelodeon...

ZYNLONTA's Japanese Push: ADC Therapeutics Gains Traction

ADC Therapeutics Eyes Japan with ZYNLONTA Bet These days, everyone seems to have their eyes on the Far East, and ADC Therapeutics is no exception. They're making a strategic leap by letting their budding blockbuster ZYNLONTA make waves in Japan. With the fresh file submitted for approval, it looks like they're hoping to capture market ground that could pay off big time...

Oxford Bank Reports Strong Q3 Amid Challenges

Digging Into Oxford Bank's Q3 Numbers You ever wonder how a smaller banking outfit yet to become a household name manages to punch above its weight? Let's look at Oxford Bank Corporation's (OTCQX: OXBC) third-quarter antics, where dreams of better margins and loan growth dance, even as operational costs spike. Net Income Climbs Despite Rising Costs The headline here is...

Bandwidth Welcomes Chip Schroeder: Key Board Makeover

Turning the Page at Bandwidth Bandwidth Inc. (NASDAQ:BAND) just shook up its executive roster by bringing in a heavy hitter. Chip Schroeder's landing on the board is a bold move from a strategic player in the cloud communications space. This guy's not your average board member; he's a veteran navigator through stormy market waters, and at Bandwidth, it seems he'll be...